DK1318837T3 - Fremgangsmåde til behandling af östrogenreceptorpositivt carcinom - Google Patents

Fremgangsmåde til behandling af östrogenreceptorpositivt carcinom

Info

Publication number
DK1318837T3
DK1318837T3 DK01961914T DK01961914T DK1318837T3 DK 1318837 T3 DK1318837 T3 DK 1318837T3 DK 01961914 T DK01961914 T DK 01961914T DK 01961914 T DK01961914 T DK 01961914T DK 1318837 T3 DK1318837 T3 DK 1318837T3
Authority
DK
Denmark
Prior art keywords
estrogen receptor
receptor positive
treating estrogen
positive carcinoma
carcinoma
Prior art date
Application number
DK01961914T
Other languages
Danish (da)
English (en)
Inventor
Yixian Zhang
Philip Frost
Tammy Michelle Sadler
Lee Martin Greenberger
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22840171&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1318837(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of DK1318837T3 publication Critical patent/DK1318837T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK01961914T 2000-08-11 2001-08-06 Fremgangsmåde til behandling af östrogenreceptorpositivt carcinom DK1318837T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22432600P 2000-08-11 2000-08-11
PCT/US2001/024615 WO2002013802A2 (en) 2000-08-11 2001-08-06 Method of treating estrogen receptor positive carcinoma

Publications (1)

Publication Number Publication Date
DK1318837T3 true DK1318837T3 (da) 2005-01-10

Family

ID=22840171

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01961914T DK1318837T3 (da) 2000-08-11 2001-08-06 Fremgangsmåde til behandling af östrogenreceptorpositivt carcinom

Country Status (14)

Country Link
US (1) US6511986B2 (cg-RX-API-DMAC7.html)
EP (1) EP1318837B1 (cg-RX-API-DMAC7.html)
JP (1) JP2004507465A (cg-RX-API-DMAC7.html)
CN (1) CN100448487C (cg-RX-API-DMAC7.html)
AR (1) AR033555A1 (cg-RX-API-DMAC7.html)
AT (1) ATE278421T1 (cg-RX-API-DMAC7.html)
AU (1) AU2001283139A1 (cg-RX-API-DMAC7.html)
CA (1) CA2416976C (cg-RX-API-DMAC7.html)
DE (1) DE60106281T2 (cg-RX-API-DMAC7.html)
DK (1) DK1318837T3 (cg-RX-API-DMAC7.html)
ES (1) ES2228932T3 (cg-RX-API-DMAC7.html)
MX (1) MXPA03001245A (cg-RX-API-DMAC7.html)
PT (1) PT1318837E (cg-RX-API-DMAC7.html)
WO (1) WO2002013802A2 (cg-RX-API-DMAC7.html)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100111928A1 (en) * 1997-05-23 2010-05-06 A & G Pharmaceutical, Inc. Methods and kits for diagnosis tumorgenicity
US6720159B1 (en) * 1997-12-16 2004-04-13 A&G Pharmaceutical, Inc. 88KDA tumorigenic growth factor and antagonists
US6309826B1 (en) 1997-05-23 2001-10-30 Ginette Serrero 88kDa tumorigenic growth factor and antagonists
US7091047B2 (en) * 1997-05-23 2006-08-15 A&G Pharmaceutical, Inc. Methods and kits for diagnosing tumorigenicity
US20030215445A1 (en) 1997-05-23 2003-11-20 Ginette Serrero Methods and compositions for inhibiting the growth of hematopoietic malignant cells
US6881548B2 (en) * 1997-05-23 2005-04-19 A&G Pharmaceutical, Inc. Methods and kits for diagnosing tumorigenicity and determining resistance to the antineoplastic effects of antiestrogen therapy
US8512960B2 (en) * 1997-05-23 2013-08-20 A&G Pharmaceutical, Inc. 88kDa tumorigenic growth factor and antagonists
US7617145B1 (en) * 2000-10-24 2009-11-10 Worldwide Farm Equipment Auctions.Com Ltd. Adaptive bidding increments in an online auction system
TWI286074B (en) 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
AU2011226833B9 (en) * 2001-02-19 2014-07-03 Novartis Ag Cancer treatment
AU2016206379B2 (en) * 2001-02-19 2017-09-14 Novartis Ag Cancer Treatment
PL231418B1 (pl) 2001-02-19 2019-02-28 Novartis Ag 40-O-( 2-hydroksyetylo)- rapamycyna do zastosowania w leczeniu guzów litych płuc, innych niż nowotwór tkanki limfatycznej
DE60231868D1 (de) * 2001-04-24 2009-05-20 Purdue Research Foundation Folat-mimetika und deren folatrezeptorbindende konjugate
WO2003005954A2 (en) * 2001-07-09 2003-01-23 Zonagen, Inc. Methods and materials for the treatment of testosterone deficiency in men
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
WO2003064383A2 (en) 2002-02-01 2003-08-07 Ariad Gene Therapeutics, Inc. Phosphorus-containing compounds & uses thereof
JP4814520B2 (ja) * 2002-05-15 2011-11-16 エンドサイト，インコーポレイテッド ビタミン−マイトマイシン結合体
US7411045B2 (en) * 2002-11-19 2008-08-12 A&G Pharmaceutical, Inc. Autocrine growth factor receptor antibodies and methods
EP2529758A3 (en) 2003-01-27 2013-01-02 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
WO2004078782A1 (en) * 2003-02-26 2004-09-16 A & G Pharmaceuticals, Inc. Methods for increasing the proliferation of b cells
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
CA2519338A1 (en) * 2003-04-22 2004-11-04 Wyeth Antineoplastic combinations
EP1644038A2 (en) * 2003-06-23 2006-04-12 A & G Pharmaceuticals, Inc. Compositions and methods for restoring sensitivity of tumor cells to antitumor therapy and inducing apoptosis
RU2345772C2 (ru) * 2003-07-25 2009-02-10 Уайт Лиофилизированные композиции cci-779
EP1660010B1 (en) * 2003-08-01 2013-07-24 A & G Pharmaceutical, Inc. Compositions and methods for restoring sensitivity to treatment with her2 antagonists
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
EP1789391B1 (en) 2004-07-23 2017-06-28 Endocyte, Inc. Bivalent linkers and conjugates thereof
KR20070070184A (ko) * 2004-10-28 2007-07-03 와이어쓰 자궁근종의 치료에 있어서 ｍＴＯＲ 억제제의 용도
MX2007009317A (es) * 2005-02-03 2008-01-30 Gen Hospital Corp Metodo para tratar cancer resistente a gefitinib.
CA2602010A1 (en) 2005-03-07 2006-09-14 Wyeth Oxepane isomer of 42-o-(2-hydroxy)ethyl-rapamycin
CN101175757B (zh) * 2005-03-16 2012-11-14 恩多塞特公司 蝶酸及其缀合物的合成和纯化
AU2006227243B2 (en) * 2005-03-22 2011-10-27 Allergan pharmaceuticals International Ltd. Dosing regimes for trans-clomiphene
JP5475992B2 (ja) * 2005-08-19 2014-04-16 エンドサイト，インコーポレイテッド 多剤リガンド結合体
WO2007022493A2 (en) * 2005-08-19 2007-02-22 Endocyte, Inc. Ligand conjugates of vinca alkaloids, analogs, and derivatives
CN103110948A (zh) 2005-11-04 2013-05-22 惠氏公司 mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
DE102006011507A1 (de) * 2006-03-14 2007-09-20 Lts Lohmann Therapie-Systeme Ag Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine
WO2008101231A2 (en) 2007-02-16 2008-08-21 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
CN101678124A (zh) * 2007-03-14 2010-03-24 恩多塞特公司 结合配体连接的微管溶素递药缀合物
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
EP3569251A1 (en) 2007-06-25 2019-11-20 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
US20090076060A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched temsirolimus
EA017385B1 (ru) 2007-10-16 2012-12-28 Репрос Терапьютикс Инк. Применение транс-кломифена для снижения концентрации глюкозы в сыворотке
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CN101909441B (zh) 2007-10-25 2015-05-13 恩多塞特公司 微管蛋白抑制剂及其制备方法
WO2010008744A2 (en) 2008-06-17 2010-01-21 Wyeth Antineoplastic combinations containing hki-272 and vinorelbine
RU2498804C2 (ru) 2008-08-04 2013-11-20 ВАЙЕТ ЭлЭлСи Противоопухолевые комбинации из 4-анилино-3-цианохинолинов и капецитабина
JP5992325B2 (ja) 2009-04-06 2016-09-14 ワイス・エルエルシー 乳癌のための、ネラチニブを活用する治療計画
PL2580210T3 (pl) 2010-06-10 2017-09-29 Seragon Pharmaceuticals, Inc. Modulatory receptora estrogenowego i ich zastosowania
UA113291C2 (xx) 2011-08-04 2017-01-10 Метаболіти транскломіфену і їх застосування
WO2013090836A1 (en) 2011-12-14 2013-06-20 Aragon Pharmaceuticals, Inc. Fluorinated estrogen receptor modulators and uses thereof
WO2013126797A1 (en) 2012-02-24 2013-08-29 Purdue Research Foundation Cholecystokinin b receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
KR20150070318A (ko) 2012-10-16 2015-06-24 엔도사이트, 인코포레이티드 비천연 아미노산을 함유하는 약물 전달 컨쥬게이트 및 사용 방법
WO2014070523A1 (en) 2012-11-02 2014-05-08 Repros Therapeutics Inc. Trans-clomiphene for use in cancer therapy
RU2560708C1 (ru) * 2014-03-24 2015-08-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт клинической и экспериментальной лимфологии" Сибирского отделения Российской академии медицинских наук (ФГБУ "НИИКЭЛ" СО РАМН) Способ воздействия на клетки гепатокарциномы в зависимости от стадии их дифференцировки нанопрепаратами лития
CN113248494A (zh) 2015-10-01 2021-08-13 奥列马制药公司 四氢-1H-吡啶[3,4-b]吲哚类抗雌激素药物
RU2747802C2 (ru) 2015-12-09 2021-05-14 Зе Боард Оф Трастис Оф Зе Юниверсити Оф Иллинойс Бензотиофеновые селективные блокаторы эстрогеновых рецепторов
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
EP3454862B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
EP3455219A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
MX2019000200A (es) 2016-07-01 2019-09-26 G1 Therapeutics Inc Agentes antiproliferativos basados en pirimidina.
NZ752443A (en) 2016-10-11 2022-11-25 Univ Duke Lasofoxifene treatment of er+ breast cancer
WO2018081168A2 (en) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective mixed estrogen receptor downregulators
EA201991622A1 (ru) 2017-01-06 2020-01-23 Г1 Терапьютикс, Инк. Комплексная терапия для лечения рака
EP3580223A4 (en) 2017-02-10 2021-01-06 G1 Therapeutics, Inc. Benzothiophene estrogen receptor modulators
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
KR102659211B1 (ko) 2017-06-29 2024-04-18 쥐원 쎄라퓨틱스, 인크. G1t38의 형체 형태 및 그의 제조 방법
CN117771239A (zh) 2018-04-10 2024-03-29 杜克大学 乳腺癌的拉索昔芬治疗
CN113453679B (zh) 2018-12-20 2025-07-08 C4医药公司 靶向蛋白降解
AU2020311337A1 (en) 2019-07-07 2022-01-20 Olema Pharmaceuticals, Inc. Regimens of estrogen receptor antagonists
US20230115865A1 (en) * 2019-10-01 2023-04-13 Sanofi Novel Substituted 6,7-Dihydro-5H-Benzo[7]Annulene Compounds, Processes for Their Preparation and Therapeutic Uses Thereof
CA3154073A1 (en) 2019-12-20 2021-06-24 Christopher G. Nasveschuk Isoindolinone and indazole compounds for the degradation of egfr
EP4114392A4 (en) 2020-03-05 2024-04-10 C4 Therapeutics, Inc. Compounds for targeted degradation of brd9
CN116490186B (zh) 2020-08-05 2025-10-31 C4医药公司 用于ret的靶向降解的化合物
CA3174245A1 (en) 2021-06-08 2022-12-15 Christopher G. Nasveschuk Therapeutics for the degradation of mutant braf
GB202116903D0 (en) 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer
EP4565585A1 (en) 2022-08-03 2025-06-11 Bristol-Myers Squibb Company Compounds for modulating ret protein
JP2025540907A (ja) 2022-11-04 2025-12-17 ブリストル－マイヤーズ スクイブ カンパニー Ｒｅｔ－ｌｄｄタンパク質分解誘導剤
KR20250116017A (ko) 2022-11-04 2025-07-31 브리스톨-마이어스 스큅 컴퍼니 Ret-ldd 단백질 억제제
WO2025006753A2 (en) 2023-06-30 2025-01-02 Merck Patent Gmbh Heterobifunctional compounds for the degradation of kras protein

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4316885A (en) 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4650803A (en) 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
US5023264A (en) 1990-07-16 1991-06-11 American Home Products Corporation Rapamycin oximes
US5023263A (en) 1990-08-09 1991-06-11 American Home Products Corporation 42-oxorapamycin
US5221670A (en) 1990-09-19 1993-06-22 American Home Products Corporation Rapamycin esters
US5130307A (en) 1990-09-28 1992-07-14 American Home Products Corporation Aminoesters of rapamycin
US5233036A (en) 1990-10-16 1993-08-03 American Home Products Corporation Rapamycin alkoxyesters
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5100883A (en) 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5118678A (en) 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5118677A (en) 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
US5162333A (en) 1991-09-11 1992-11-10 American Home Products Corporation Aminodiesters of rapamycin
US5151413A (en) 1991-11-06 1992-09-29 American Home Products Corporation Rapamycin acetals as immunosuppressant and antifungal agents
US5177203A (en) 1992-03-05 1993-01-05 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
US5256790A (en) 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5489680A (en) 1992-10-13 1996-02-06 American Home Products Corporation Carbamates of rapamycin
US5302584A (en) 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
US5434260A (en) 1992-10-13 1995-07-18 American Home Products Corporation Carbamates of rapamycin
US5480989A (en) 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5480988A (en) 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5411967A (en) 1992-10-13 1995-05-02 American Home Products Corporation Carbamates of rapamycin
US5262423A (en) 1992-10-29 1993-11-16 American Home Products Corporation Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents
US5258389A (en) 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
US5260300A (en) 1992-11-19 1993-11-09 American Home Products Corporation Rapamycin carbonate esters as immuno-suppressant agents
US5504091A (en) 1993-04-23 1996-04-02 American Home Products Corporation Biotin esters of rapamycin
US5391730A (en) 1993-10-08 1995-02-21 American Home Products Corporation Phosphorylcarbamates of rapamycin and oxime derivatives thereof
US5373014A (en) 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
US5378836A (en) 1993-10-08 1995-01-03 American Home Products Corporation Rapamycin oximes and hydrazones
US5385909A (en) 1993-11-22 1995-01-31 American Home Products Corporation Heterocyclic esters of rapamycin
US5385910A (en) 1993-11-22 1995-01-31 American Home Products Corporation Gem-distributed esters of rapamycin
US5385908A (en) 1993-11-22 1995-01-31 American Home Products Corporation Hindered esters of rapamycin
US5389639A (en) 1993-12-29 1995-02-14 American Home Products Company Amino alkanoic esters of rapamycin
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5463048A (en) 1994-06-14 1995-10-31 American Home Products Corporation Rapamycin amidino carbamates
US5491231A (en) 1994-11-28 1996-02-13 American Home Products Corporation Hindered N-oxide esters of rapamycin
US5563145A (en) 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
US5780462A (en) 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
US5998402A (en) 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
DE19624668A1 (de) 1996-06-20 1998-02-19 Klinge Co Chem Pharm Fab Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors

Also Published As

Publication number Publication date
HK1056687A1 (en) 2004-02-27
WO2002013802A2 (en) 2002-02-21
CA2416976C (en) 2008-05-20
ES2228932T3 (es) 2005-04-16
EP1318837A2 (en) 2003-06-18
PT1318837E (pt) 2004-12-31
US6511986B2 (en) 2003-01-28
AR033555A1 (es) 2003-12-26
CA2416976A1 (en) 2002-02-21
DE60106281D1 (de) 2004-11-11
US20020045638A1 (en) 2002-04-18
CN1446106A (zh) 2003-10-01
CN100448487C (zh) 2009-01-07
WO2002013802A3 (en) 2003-03-27
MXPA03001245A (es) 2003-05-27
DE60106281T2 (de) 2005-02-24
ATE278421T1 (de) 2004-10-15
EP1318837B1 (en) 2004-10-06
JP2004507465A (ja) 2004-03-11
AU2001283139A1 (en) 2002-02-25

Similar Documents

Publication Publication Date Title
DK1318837T3 (da) Fremgangsmåde til behandling af östrogenreceptorpositivt carcinom
DK1132569T3 (da) Fremgangsmåde til behandling af en underjordisk formation
DK1292594T3 (da) Quinazolinderivater til behandling af tumorer
DK1071745T3 (da) Fremgangsmåde til syntetisering af COX-2-inhibitorer
DK1305411T3 (da) Fremgangsmåde til frembringelse af funktionelle proteindomæner
NO20031505D0 (no) Sementskomontasje for monoboret brönn
DK1303478T3 (da) Fremgangsmåde til fremstilling af substituerede octanoylamider
DK1008577T3 (da) Fremgangsmåde til fremstilling af methanol
DK1296935T3 (da) Fremgangsmåde til fremstilling af substituerede octanoylamider
DK1339678T3 (da) Selektive agonister til EP4-receptor til behandling af osteoporose
DK0962626T3 (da) Fremgangsmåde til behandling af underjordiske formationer
DK1326841T3 (da) Pyridinon-derivater til behandling af atherosklerose
DK1150966T3 (da) Fremgangsmåde til fremstilling af 5-cyanophthalid
DK1063990T3 (da) Anvendelse af Biochanin-beriget ekstrakt til behandling af östrogen-associerede lidelser
DK1309555T3 (da) Metode til fremstilling af amlodipinmaleat
DK1230247T3 (da) Fremgangsmåde til stabilisering af siloxanforbindelser
DK1309582T3 (da) Fremgangsmåde til fremstilling af citalopram
DK2189162T3 (da) Fremgangsmåder til behandling af cellulære proliferative forstyrrelser
DK1140824T3 (da) Fremgangsmåde til fremstilling af 3-alkanoyl- og 3-alkylindoler
DK1314824T3 (da) Fremgangsmåde til konsolidering af jord
DK1142990T3 (da) Fremgangsmåde til fremstilling af transglutaminase
DK1089950T3 (da) Fremgangsmåde til forbedring af en undergrunds egenskaber
DK1326836T3 (da) Fremgangsmåde til fremstilling af 3-amino-2-chlor-4-methylpyridin
DK1294659T3 (da) Fremgangsmåde til isolering af katamin
DK1309323T3 (da) Fremgangsmåde til behandling af angiogeneserelaterede lidelser